BEMYGENE

(Biotechnology, Medicine and Health)

Introduction

Bemygene Health Company is a new company of a bio-medical character, specialised in offering a service of early detection, cancer prevention and genetic counseling.

There are two main components of early cancer detection:  education to promote early diagnosis and screening.

The main objective of the Bemygene Health Company® is to inform the population of the importance of early diagnosis, to offer excellent patient service and guarantee the population a “vanguard” genetic diagnosis service, through progressive and “exclusive” incorporation of those products which have been validated and accredited by the relevant international and national entities, in order to position themselves as a leader in the field of predictive and personalised oncological medicine.

 

The information contained in this business data sheep has been provided by the company and the University of Valencia Science Park Foundation (FPCUV) is not responsible for its content.

Download Impulse to Business Development Programme (PIDE)'s file
BEMYGENE

Technology offer

Technical Specifications
  • The first Spanish company with a scientific and bio-medical base specialised in offering advanced non-invasive cancer prevention and genetic counselling services.
  • They provide the patient with the latest advances in the field, within a rigorous framework of genetic counselling, state-of-the-art technology and bio-medical expertise.
Benefits of Technology
  • Performing early detection screening can help doctors find and treat several types of cancer early.  According to the WHO, the early detection of cancer greatly increases the chances that a treatment will be effective.
  • Some current screening tests can cause health problems, however, thanks to new technologies and advances in cancer research, BEMYGENE can detect early cancer bio-markers, using non-invasive and innocuous techniques.
Technology Applications
  • They offer the most reliable, comfortable and validated genetic tests on the market, accompanied by a personalised attention to each of their patients.   This allows patients needs to be identified and for them to be advised with respect to their decision-making.

BEMYGENE company news

Bemygene and La Fe will develop an epigenetic analysis to diagnose lung cancer when biopsy is not feasibleRead more »

Contact information

Teresa Valdés Sánchezinfo@bemygene.com Phone: (+34) 962 062 223